Targets › GALC
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jun 2028.
Lysosomal hydrolase that removes the terminal galactose from galactosylceramide, a major lipid of the myelin sheath, kidney, and epithelial cells of the small intestine and colon, and from related glycosphingolipids such as galactosylsphingosine. Present at very low abundance/specific activity in tissues relative to other lysosomal enzymes. (UniProt, P54803)
Open in Phaseline: the race on GALC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Duke University | FBX-101 AAVrh.10 vector expressing human galactocerebrosidase (GALC) cDNA | GALC | Phase 1 | Krabbe Disease | Jun 2028 |
Krabbe Disease (1)
protein or peptide (1)
Duke University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.